Yonsei Med J.  2020 Sep;61(9):826-830. 10.3349/ymj.2020.61.9.826.

Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection

Affiliations
  • 1Division of Pulmonary and Critical Care Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
  • 2Division of Pulmonary and Critical Care Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea.
  • 3Division of Pulmonology, Department of Internal Medicine, Keimyung University Dongsan Hospital Keimyung University School of Medicine, Daegu
  • 4Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
  • 5Division of Pulmonary and Critical Care Medicine, Daegu Fatima Hospital, Daegu, Korea.
  • 6Division of Pulmonary and Critical Care Medicine, Yeungnam University Medical Center, Daegu, Korea.

Abstract

We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.

Keyword

Coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; darunavir-cobicistat
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr